Apolipoprotein E, receptors, and modulation of Alzheimer's disease
Apolipoprotein E (apoE) is a lipid carrier in both the peripheral and the central nervous
systems. Lipid-loaded apoE lipoprotein particles bind to several cell surface receptors to …
systems. Lipid-loaded apoE lipoprotein particles bind to several cell surface receptors to …
Insulin in the brain: there and back again
WA Banks, JB Owen, MA Erickson - Pharmacology & therapeutics, 2012 - Elsevier
Insulin performs unique functions within the CNS. Produced nearly exclusively by the
pancreas, insulin crosses the blood–brain barrier (BBB) using a saturable transporter …
pancreas, insulin crosses the blood–brain barrier (BBB) using a saturable transporter …
Clearance of amyloid-β peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease
R Deane, RD Bell, A Sagare… - CNS & Neurological …, 2009 - ingentaconnect.com
The main receptors for amyloid-beta peptide (Aβ) transport across the blood-brain barrier
(BBB) from brain to blood and blood to brain are low-density lipoprotein receptor related …
(BBB) from brain to blood and blood to brain are low-density lipoprotein receptor related …
[HTML][HTML] Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders
VK Ramanan, AJ Saykin - American journal of neurodegenerative …, 2013 - ncbi.nlm.nih.gov
The discovery of causative genetic mutations in affected family members has historically
dominated our understanding of neurodegenerative diseases such as Alzheimer's disease …
dominated our understanding of neurodegenerative diseases such as Alzheimer's disease …
Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease
AP Sagare, RD Bell… - Cold Spring …, 2012 - perspectivesinmedicine.cshlp.org
Neurovascular dysfunction is an integral part of Alzheimer disease (AD). Changes in the
brain vascular system may contribute in a significant way to the onset and progression of …
brain vascular system may contribute in a significant way to the onset and progression of …
Low‐density lipoprotein receptor‐related protein‐1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β‐peptide elimination from the brain
BV Zlokovic, R Deane, AP Sagare… - Journal of …, 2010 - Wiley Online Library
J. Neurochem.(2010) 115, 1077–1089. Abstract Low‐density lipoprotein receptor‐related
protein‐1 (LRP1), a member of the low‐density lipoprotein receptor family, has major roles …
protein‐1 (LRP1), a member of the low‐density lipoprotein receptor family, has major roles …
Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism
JM Cooper, A Lathuiliere, M Migliorini, AL Arai… - Journal of Biological …, 2021 - ASBMB
In Alzheimer's disease (AD), pathological forms of tau are transferred from cell to cell and"
seed" aggregation of cytoplasmic tau. Phosphorylation of tau plays a key role in …
seed" aggregation of cytoplasmic tau. Phosphorylation of tau plays a key role in …
Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier
S Krol, R Macrez, F Docagne, G Defer… - Chemical …, 2013 - ACS Publications
Nanotechnology is an area of growing public interest. Its attractiveness stems from the
promise offered socially and economically by the recent significant advances in …
promise offered socially and economically by the recent significant advances in …
Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities
AP Sagare, R Deane, BV Zlokovic - Pharmacology & therapeutics, 2012 - Elsevier
Low-density lipoprotein receptor-related protein-1 (LRP1) is the main cell surface receptor
involved in brain and systemic clearance of the Alzheimer's disease (AD) toxin amyloid-beta …
involved in brain and systemic clearance of the Alzheimer's disease (AD) toxin amyloid-beta …
Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease
AP Sagare, RD Bell, BV Zlokovic - Journal of Alzheimer's …, 2013 - content.iospress.com
The evidence that neurovascular dysfunction is an integral part of Alzheimer's disease (AD)
pathogenesis has continued to emerge in the last decade. Changes in the brain vasculature …
pathogenesis has continued to emerge in the last decade. Changes in the brain vasculature …